Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaniprevir + Peg-IFN + RBV in Japanese Treatment-Naïve CHC GT1
NCT01370642Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vaniprevir in hepatitis C (HCV), sponsored by Merck & Co.. Started Jun 2011; status: completed.
02
Drugs
vaniprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01370642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01370642.